In the per-protocol cohort , the QIV efficacy was @ % ( @ % CI , @ to @ ) , and the efficacy against culture-confirmed influenza @ % ( @ % CI , @ to @ ) ; the efficacy among children with moderate-to-severe influenza was @ % ( @ % CI , @ to @ ) .